Indian drug major Sun Pharma Industries (BSE: 524715) dipped just 1% to 962.60 rupees, despite the company announcing a setback in the development of its newly-acquired product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of alopecia areata, an autoimmune dermatological disease – which is in late-stage development.
Following a recent submission to the US Food and Drug Administration (FDA), Sun Pharm said it had a teleconference call with the agency, regarding a pulmonary embolism (serious adverse events) occurring at the 12mg BID dose in one of the long-term open label extension (OLE) studies with deuruxolitinib.
Sun Pharma, India's largest drugmaker by revenue, acquired deuruxolitinib when it bought USA-based Concert Pharmaceuticals for $576 million earlier this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze